FDA relents from midodrine withdrawal plan

Sep 06, 2010

(AP) -- Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

Food and Drug Administration representative Sandy Walsh said in an emailed statement that the agency will continue to allow access to ProAmatine, also known as midodrine, "while the necessary data is collected and the legal issues get sorted out."

Roughly 100,000 U.S. patients received prescriptions for ProAmatine or generic versions last year, according to the FDA. The drug is approved to treat orthostatic hypotension, a type of low that causes patients to become dizzy or faint when standing upright.

Last month, the FDA proposed withdrawing the drug from the market and giving Shire, which is based in Ireland, an opportunity to schedule a hearing to discuss the matter. It had approved ProAmatine in 1996 based on promising early results in treating low blood pressure. But a mandatory follow-up study to actually prove the long-term benefits of the drug was never conducted.

Shire acquired the drug when it bought Roberts Pharmaceuticals in 2000. Shire spokeswoman Jessica Mann said the drugmaker did conduct follow-up trials and submitted data in 2005 that it believes showed its effectiveness. The company plans to continue to work with the FDA.

Shire had said it was planning to withdraw the drug from the market by Sept. 30. But the company no longer intends to do so.

"It's our goal to do what we can to ensure that this treatment is still available to patients," Mann said.

The FDA's letter marked the first time it threatened to pull a drug off the market due to missing follow-up data, though it has long held that power. FDA spokeswoman Sandy Walsh said in an e-mail the issue "continues to evolve," and that it will know more in the coming weeks.

Copies of the letter also were sent to five generic drugmakers who make the drug, including Mylan Inc. and AG unit Sandoz Inc. The generic versions would also be subject to a market withdrawal, unless their manufacturers complete the study requested by the FDA.

Explore further: FDA approves new drug for rare genetic disease

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA poised to recall unproven blood pressure drug

Aug 16, 2010

(AP) -- Federal health regulators are pushing to withdraw a blood pressure drug that has been on the market for 14 years in spite of the manufacturer's failure to submit evidence that it actually helps patients.

GAO: FDA fails to follow up on unproven drugs

Oct 26, 2009

(AP) -- The Food and Drug Administration has allowed drugs for cancer and other diseases to stay on the market even when follow-up studies showed they didn't extend patients' lives, say congressional investigators.

FDA approves a new beta blocker

Dec 18, 2007

The U.S. Food and Drug Administration has approved Bystolic, a beta blocker, for the treatment of high blood pressure. Bystolic (nebivolol) is a new drug not previously approved for use in the United States.

Recommended for you

Boxed warnings are common in novel therapeutics

22 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0